Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05698017
PHASE1
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Sponsor: Cytora Ltd.
View on ClinicalTrials.gov
Summary
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
Official title: Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2022-11-07
Completion Date
2026-02-19
Last Updated
2025-01-29
Healthy Volunteers
No
Interventions
BIOLOGICAL
hOMSC300
Human Oral Mucosa Stem Cells
Locations (1)
Tel-Aviv Sourasky Medical Center (Ichilov)
Tel Aviv, Israel